glp 1 for kidney disease Glucagon-like Peptide Receptor Agonists and Outcomes in the Era of Personalized Medicine: Focus on Albuminuria Recommendations for SGLT2i versus GLP-1

Forward-Looking Statements This press release contains forward-looking statements that are based on the current beliefs and expectations of Daewoong Pharmaceutical's management

CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH), a 29-amino-acid peptide modified with a Drug Affinity Complex (DAC) that extends its biological half-life from minutes to several days

Nejman, D

Lawsuits Filed Against Eli Lilly Along with Novo Nordisk, Eli Lilly and Company faces a growing number of lawsuits involving its GLP-1 receptor agonist drugs

Patti AM, Nikolic D, Magan-Fernandez A, Giglio RV, Castellino G, Chianetta R, et al

LLY showed potent ACE inhibition (IC = 44.16 2.45 M) and remained stable across varied pH, moderate heat, metal ions, glucose, and salt